LGND Stock Balance Sheets

Ligand Pharmaceuticals Quarterly Balance Sheets Chart

Quarterly

Annual

Goodwill

Account Receivables

Cash and Cash Eq

Account Payables

Deferred Revenue

Inventory

Ligand Pharmaceuticals Quarterly Balance Sheets Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-06-30	2004-03-31	2003-09-30	2003-06-30	2003-03-31	2002-12-31	2002-09-30

assets
current assets:
cash and cash equivalents	67,669,000	47,989,000	72,307,000	63,619,000	18,139,000	50,093,000	22,954,000	19,275,000	28,445,000	88,728,000	45,006,000	4,116,000	5,280,000	14,993,000	19,522,000	23,430,000	21,863,000	31,853,000	47,619,000	456,916,000	115,156,000	117,527,000	71,543,000	225,302,000	273,047,000	105,113,000	117,164,000	115,560,000	151,459,000	51,024,000	20,620,000	32,739,000	60,223,000	10,641,000	18,752,000	86,580,000	61,350,000	31,293,000	97,428,000	93,770,000	108,238,000	165,766,000	160,203,000	180,663,000	14,537,000	12,977,000	11,639,000	3,271,000	5,923,000	5,037,000	12,381,000	7,046,000	8,885,000	9,777,000	7,041,000	2,251,000	3,441,000	6,033,000	3,346,000	3,796,000	3,235,000	4,044,000	16,032,000	5,160,000	3,549,000	4,920,000	28,753,000	11,801,000	29,177,000	59,543,000	76,812,000	69,301,000	103,611,000	403,911,000	158,401,000	10,029,000	41,615,000	49,808,000	66,756,000	49,588,000	32,580,000	50,956,000	92,310,000	41,920,000	65,558,000	73,002,000	24,248,000	12,979,000	42,423,000	23,177,000
short-term investments	177,351,000	160,912,000	183,858,000	156,024,000	208,793,000	260,500,000	147,355,000	171,227,000	190,596,000	193,937,000	166,864,000	117,291,000	142,655,000	189,006,000	321,586,000	299,781,000	279,972,000	307,354,000	363,567,000	338,154,000	694,724,000	621,284,000	939,989,000	874,383,000	1,059,002,000	1,323,575,000	601,217,000	891,128,000	805,468,000	213,329,000	181,041,000	169,520,000	112,404,000	148,733,000	122,296,000	37,535,000	45,603,000	81,908,000	102,791,000	93,528,000	73,371,000	11,459,000	7,133,000	5,925,000	7,490,000	12,275,000	4,340,000						1,500,000	1,517,000	10,000,000	10,000,000	10,000,000	10,487,000	19,351,000	20,273,000	28,960,000	35,012,000	37,200,000	39,033,000	51,961,000	47,684,000	51,918,000	59,311,000	55,819,000	30,685,000	17,596,000	29,091,000	11,789,000	6,319,000	13,447,000	21,862,000	19,168,000	17,897,000	20,174,000	24,202,000	35,694,000	38,449,000								12,099,000
accounts receivable	41,288,000	38,492,000	38,376,000	34,318,000	37,481,000	28,435,000	32,917,000	36,003,000	27,994,000	29,188,000	30,424,000	65,168,000	62,308,000	41,797,000	85,453,000	64,336,000	58,156,000	54,436,000	56,847,000	32,907,000	41,874,000	39,506,000	30,387,000	21,958,000	20,259,000	26,615,000	55,850,000	46,976,000	42,001,000	37,108,000	25,596,000	12,816,000	13,462,000	7,057,000	14,700,000	6,586,000	9,966,000	11,779,000	6,170,000	5,517,000	5,532,000	7,423,000	12,634,000	5,812,000	3,133,000	4,673,000	2,222,000	5,507,000	699,000	4,622,000	4,589,000	2,157,000	817,000	1,992,000	6,110,000	1,719,000	1,038,000	1,383,000	993,000	96,000		298,000	618,000	2,110,000	1,050,000	2,715,000						14,000	50,000	1,269,000	11,521,000	7,077,000	18,667,000	20,046,000	20,954,000	24,378,000	21,016,000	18,324,000	30,847,000	17,936,000	14,185,000	9,923,000	7,689,000	17,086,000	7,356,000	7,001,000
inventory	15,489,000	14,614,000	14,114,000	16,740,000	18,672,000	21,337,000	23,969,000	25,392,000	26,906,000	14,011,000	13,294,000	22,326,000	24,773,000	25,614,000	27,326,000	32,996,000	39,946,000	36,932,000	26,487,000	13,430,000	3,702,000	7,320,000	7,296,000	6,565,000	9,638,000	11,905,000	7,124,000	8,136,000	9,520,000	10,531,000	4,373,000	5,007,000	6,809,000	7,629,000	1,923,000	4,027,000	3,835,000	1,750,000	1,633,000	1,221,000	802,000	2,821,000	269,000	1,071,000	817,000	1,949,000	1,392,000	1,838,000	2,265,000	2,838,000	1,697,000	2,548,000	2,698,000	1,345,000	1,301,000	1,960,000	2,594,000	4,212,000
short-term portion of financial royalty assets	10,276,000
income taxes receivable	828,000	4,339,000	4,073,000	7,813,000			6,395,000				4,614,000	785,000	964,000		6,193,000	6,378,000	4,694,000	1,145,000	2,217,000		2,679,000	7,271,000	11,361,000
other current assets	4,816,000	13,285,000	16,897,000	19,741,000	7,122,000	7,311,000	2,657,000	2,097,000	2,770,000	2,331,000	3,399,000	10,746,000	7,804,000	4,656,000	4,671,000	5,161,000	6,270,000	5,708,000	3,822,000	3,191,000	5,489,000	4,940,000	4,734,000	5,039,000	5,672,000	9,228,000	20,418,000	25,339,000	12,817,000	5,647,000	1,514,000	1,112,000	1,072,000	641,000	2,175,000	2,756,000	2,602,000	1,562,000	1,908,000	1,777,000	1,801,000	926,000	1,520,000	1,602,000	1,123,000	841,000	959,000	1,512,000	1,211,000	986,000	829,000	1,015,000	2,025,000	2,778,000	1,344,000	1,663,000	1,868,000	1,151,000	720,000	1,342,000	1,430,000	1,317,000	1,364,000	1,667,000	1,392,000	1,179,000	2,300,000	4,029,000	2,434,000	3,020,000	5,068,000	2,629,000	2,771,000	4,567,000	9,518,000	12,465,000	25,986,000	16,357,000	15,750,000	12,672,000	12,924,000	17,076,000	17,713,000	3,245,000	3,764,000	3,188,000	2,635,000	6,547,000	7,308,000	2,835,000
assets held for sale	35,228,000	29,685,000																		13,143,000																																											3,170,000
total current assets	352,945,000	309,316,000	331,559,000	309,388,000	312,259,000	368,913,000	237,429,000	253,994,000	276,711,000	328,195,000	263,601,000	220,432,000	243,784,000	276,066,000	464,751,000	432,082,000	410,901,000	437,428,000	500,559,000	857,741,000	863,624,000	830,727,000	1,123,645,000	1,183,103,000	1,442,307,000	1,567,895,000	870,540,000	1,745,225,000	1,480,470,000	349,051,000	237,021,000	224,201,000	197,177,000	174,701,000	163,053,000	140,691,000	126,563,000	133,059,000	215,572,000	210,324,000	196,725,000	191,713,000	185,158,000	198,520,000	28,585,000	33,403,000	24,881,000	16,635,000	14,570,000	17,740,000	23,823,000	17,434,000	21,096,000	23,544,000	32,230,000	26,817,000	28,139,000	31,296,000	37,019,000	35,287,000	43,402,000	50,387,000	68,166,000	59,895,000	69,470,000	67,695,000	93,929,000	85,965,000	96,112,000	101,899,000	109,943,000	115,775,000	132,183,000	427,947,000	235,557,000	64,527,000	113,903,000	112,340,000	132,967,000	117,708,000	108,542,000	131,701,000	172,824,000	118,811,000	124,902,000	105,862,000	56,973,000	63,011,000	83,753,000	48,267,000
intangible assets	250,133,000	258,391,000	266,648,000	274,905,000	283,162,000	291,420,000	299,606,000	314,843,000	325,377,000	333,916,000	342,455,000	517,025,000	528,364,000	539,707,000	551,040,000	562,372,000	572,006,000	583,785,000	595,330,000	224,582,000	215,295,000	206,520,000	210,448,000	216,268,000	212,609,000	216,290,000	219,793,000	216,276,000	222,001,000	225,306,000	228,584,000	196,578,000	199,284,000	201,990,000	204,705,000	207,435,000	210,142,000	212,823,000	48,347,000	48,941,000	49,535,000	50,129,000	50,723,000	51,317,000	51,911,000	52,505,000	53,099,000	53,692,000	54,245,000	55,319,000	55,912,000	56,580,000	56,273,000	56,855,000	57,437,000
goodwill	101,541,000	101,541,000	105,250,000	105,250,000	105,250,000	105,250,000	103,370,000	103,770,000	105,673,000	105,673,000	105,673,000	181,206,000	181,206,000	181,206,000	181,206,000	190,183,000	190,517,000	190,515,000	189,662,000	102,136,000	103,369,000	94,341,000	95,229,000	93,513,000	88,000,000	86,809,000	86,646,000	85,961,000	85,961,000	85,961,000	85,959,000	72,207,000	72,207,000	72,207,000	72,207,000	72,359,000	72,360,000	72,997,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	12,238,000	14,894,000	14,894,000	14,894,000
long-term portion of financial royalty assets	193,556,000	188,320,000	185,024,000	199,251,000	80,481,000	65,710,000
noncurrent derivative assets	17,958,000	18,029,000	10,583,000	19,246,000	34,505,000
property and equipment	3,632,000	3,623,000	15,133,000	15,094,000	14,970,000	15,135,000	15,607,000	16,178,000	11,382,000	11,743,000	12,482,000	33,418,000	30,954,000	24,584,000	20,511,000	18,702,000	17,628,000	16,896,000	14,434,000	7,157,000	7,883,000	6,690,000	7,185,000	6,411,000	6,268,000	5,575,000	5,372,000	4,407,000	4,187,000	4,119,000	4,212,000	3,526,000	1,875,000	1,898,000	1,819,000	1,826,000	1,181,000	567,000	372,000	355,000	405,000	440,000	486,000	551,000	619,000	690,000	867,000	834,000	804,000	758,000	788,000	853,000	644,000	375,000	455,000	678,000	679,000	795,000	559,000	968,000	7,073,000	7,772,000	8,522,000	9,893,000	10,459,000	11,195,000	12,903,000	1,687,000	2,024,000	2,091,000	2,865,000	3,434,000	3,783,000	4,022,000	5,551,000	21,453,000	21,561,000	21,758,000	22,483,000	22,638,000	22,927,000	23,275,000	23,647,000	23,910,000	23,620,000	9,072,000	8,843,000	9,229,000	9,672,000	10,152,000
lease right-of-use assets	7,991,000	6,869,000
other investments	10,908,000	10,908,000	10,908,000	11,908,000	10,741,000	36,500,000	35,726,000
deferred income taxes	829,000	546,000	72,000	78,000	190,000		214,000	8,530,000	8,530,000	875,000	8,530,000	35,500,000	35,654,000	35,655,000	34,482,000	26,728,000	27,882,000	27,432,000	24,320,000	27,026,000	26,411,000	26,358,000	25,608,000				46,521,000	32,440,000	44,586,000	69,368,000	84,422,000	134,939,000	138,837,000	141,007,000	123,891,000	133,486,000	161,076,000	157,258,000	216,564,000	7,517,000	3,059,000	2,797,000		1,214,000	1,104,000	1,151,000		8,000	8,000	791,000		237,000	237,000	237,000	237,000	1,194,000	1,169,000	1,021,000		25,068,000	25,068,000	25,068,000	25,068,000
other assets	9,111,000	7,892,000	6,924,000	8,404,000	11,922,000	11,225,000	5,923,000	8,426,000	4,495,000	4,634,000	4,736,000	6,279,000	6,316,000	6,442,000	2,741,000	3,095,000	2,828,000	3,053,000	4,267,000	13,704,000	6,059,000	1,270,000	2,357,000	2,488,000	1,680,000	6,396,000	471,000	499,000	642,000	894,000	4,859,000	2,028,000	1,668,000	1,821,000	1,744,000	1,744,000	603,000	70,000	27,000	248,000	301,000	358,000	207,000	230,000	253,000	275,000	299,000	344,000	394,000	451,000	517,000	416,000	524,000	563,000	738,000	777,000	773,000	883,000	838,000	5,453,000	5,494,000	5,537,000	5,081,000	101,000	101,000	101,000	144,000								36,000	1,264,000	3,665,000	4,011,000	4,704,000	5,597,000	5,928,000	6,326,000	6,174,000	8,420,000	8,822,000	11,134,000	11,718,000	12,333,000	17,992,000	22,163,000
total assets	948,604,000	905,435,000	941,774,000	954,866,000	866,405,000	913,869,000	787,216,000	769,226,000	758,105,000	811,076,000	762,668,000	1,050,605,000	1,076,288,000	1,105,184,000	1,297,590,000	1,273,656,000	1,256,283,000	1,295,121,000	1,362,285,000	1,247,449,000	1,242,936,000	1,185,917,000	1,494,915,000	1,547,476,000	1,801,836,000	1,913,988,000	1,260,803,000	2,105,742,000	1,858,284,000	754,668,000	671,021,000	662,337,000	640,024,000	629,723,000	601,585,000	600,865,000	616,799,000	613,438,000	533,929,000	521,700,000	304,762,000	263,223,000	258,029,000	272,283,000	99,847,000	105,471,000	104,713,000	101,677,000	99,571,000	98,363,000	104,260,000	97,506,000	104,594,000	111,798,000	122,350,000	122,466,000	127,435,000	134,153,000	75,559,000	112,568,000	127,597,000	133,620,000	141,807,000	117,086,000	129,176,000	139,587,000	171,448,000	147,191,000	160,023,000	166,265,000	173,278,000	211,524,000	228,476,000	524,810,000	326,053,000	231,867,000	285,932,000	288,689,000		306,047,000	301,723,000	313,253,000		285,317,000	294,189,000	272,797,000
liabilities and stockholders' equity
current liabilities:
accounts payable	8,584,000	5,366,000	5,233,000	4,694,000	1,793,000	1,893,000	2,427,000	2,475,000	9,582,000	6,135,000	5,307,000	15,887,000	19,153,000	6,972,000	8,403,000	7,233,000	17,273,000	9,469,000	3,784,000	10,169,000	6,103,000	3,365,000	2,420,000	2,040,000	2,888,000	5,061,000	4,183,000	1,647,000	2,682,000	3,407,000	2,259,000	3,617,000	1,799,000	6,456,000	2,734,000	2,757,000	2,336,000	2,688,000	4,083,000	3,143,000	2,708,000	7,442,000	7,698,000	4,864,000	5,059,000	3,675,000	3,951,000	4,304,000	4,755,000	5,522,000	5,854,000	6,027,000	6,746,000	7,893,000	11,065,000	10,072,000	10,628,000	13,032,000	8,597,000	11,339,000	13,445,000	14,519,000	16,945,000	14,379,000	14,844,000	15,641,000	14,627,000	9,014,000	10,290,000	10,760,000	12,682,000	10,448,000	10,939,000	13,181,000	12,259,000	16,080,000	19,460,000	16,325,000	15,360,000	9,809,000	14,276,000	14,586,000	17,352,000	20,225,000	16,866,000	17,261,000	10,819,000	13,441,000	11,979,000	9,662,000
accrued liabilities	17,464,000	23,537,000	27,906,000	15,600,000	12,171,000	12,430,000	12,467,000	10,635,000	7,291,000	14,977,000	15,681,000	19,338,000	14,551,000	15,877,000	17,579,000	12,237,000	10,107,000	12,110,000	18,530,000	14,498,000	12,828,000	11,848,000	9,836,000	13,060,000	11,540,000	14,771,000	19,200,000	9,267,000	9,312,000	8,480,000	7,377,000	6,423,000	5,325,000	4,680,000	6,397,000	6,675,000	4,951,000	3,669,000	5,397,000	4,156,000	5,629,000	4,263,000	4,866,000	4,311,000	3,241,000	5,451,000	5,337,000	4,619,000	4,021,000	4,518,000	4,961,000	5,381,000	4,228,000	4,143,000	8,262,000	7,480,000	6,814,000	11,904,000	8,859,000	7,566,000	5,172,000	5,581,000	9,375,000	12,411,000	6,921,000	7,771,000	12,665,000	29,183,000	22,698,000	21,698,000	24,327,000	30,870,000	39,204,000	57,380,000	46,509,000	52,902,000	58,302,000	43,502,000	59,587,000	53,737,000	42,864,000	45,716,000	43,908,000	36,108,000					11,786,000
income taxes payable	305,000	1,803,000		2,108,000	2,091,000	1,138,000		1,204,000	11,387,000			9,703,000	3,782,000							674,000
deferred revenue	111,000	101,000	1,278,000	1,152,000	1,196,000	1,227,000	1,222,000			257,000	355,000	9,547,000	10,584,000	10,503,000	10,996,000	12,007,000	17,147,000	25,107,000	29,435,000	5,404,000	8,917,000	4,354,000	2,139,000	2,230,000	939,000	2,808,000	3,286,000	2,450,000																																								2,546,000	2,546,000	2,546,000
current contingent liabilities	1,465,000	1,484,000	206,000	128,000	146,000	127,000	256,000			67,000	57,000	1,773,000	2,258,000	1,524,000	2,588,000	2,594,000	5,650,000	41,509,000	39,884,000	1,194,000	1,416,000	871,000	2,607,000	1,794,000	4,763,000	4,666,000	5,717,000	3,678,000	7,495,000	7,545,000	4,703,000	86,000	86,000	111,000	5,088,000	5,079,000	5,337,000	5,285,000	10,414,000	7,620,000	7,674,000	3,692,000		4,184,000
current operating lease liabilities	1,089,000	859,000	1,266,000	1,066,000	1,156,000	1,000,000	403,000	497,000	680,000	660,000	670,000	2,345,000	2,501,000	1,850,000	2,053,000	2,181,000	2,275,000	2,173,000	1,885,000
current finance lease liabilities	24,000	24,000	24,000	24,000	12,000	3,000	7,000				45,000				46,000				6,593,000
liabilities related to assets held for sale	35,692,000	25,509,000																		10,361,000
total current liabilities	64,734,000	58,683,000	37,112,000	24,772,000	18,565,000	17,818,000	16,782,000	15,727,000	29,388,000	98,929,000	98,810,000	135,241,000	167,853,000	42,578,000	41,665,000	36,297,000	52,497,000	95,805,000	100,111,000	42,300,000	29,264,000	20,438,000	17,002,000	35,695,000	108,985,000	186,777,000	82,249,000	793,344,000	632,850,000	246,979,000	238,868,000	231,683,000	225,840,000	226,995,000	227,129,000	226,131,000	220,347,000	12,240,000	20,836,000	16,253,000	17,949,000	18,157,000	22,779,000	18,433,000	18,621,000	21,005,000	28,939,000	32,461,000	32,571,000	33,017,000	35,439,000	29,879,000	30,419,000	27,206,000	43,643,000	42,454,000	42,315,000	44,570,000	33,488,000	36,680,000	43,598,000	41,434,000	52,172,000	53,047,000	48,202,000	52,884,000	70,614,000	51,701,000	44,612,000	44,311,000	50,968,000	59,832,000	68,058,000	340,501,000	170,810,000	226,415,000	268,412,000	256,029,000	235,211,000	224,595,000	213,481,000	216,216,000	216,712,000	61,470,000	57,258,000	46,290,000	35,154,000	37,823,000	30,535,000	27,610,000
long-term deferred revenue			2,246,000	2,508,000	2,696,000	3,065,000	1,444,000					5,537,000	7,428,000																	3,000,000	3,525,000									2,083,000	2,083,000	2,085,000		2,085,000
long-term contingent liabilities	4,097,000	4,026,000	3,475,000	3,863,000	4,052,000	2,888,000	2,942,000	3,515,000	3,505,000	2,776,000	3,456,000	6,855,000	6,961,000	7,448,000	8,483,000	6,782,000	9,121,000	9,548,000	9,249,000	9,604,000	10,005,000	5,811,000	6,335,000	7,995,000	8,314,000	8,955,000	6,825,000	9,053,000	8,146,000	6,376,000	9,258,000	5,196,000	3,860,000	3,035,000	2,916,000	3,933,000	4,138,000	4,022,000	3,033,000	7,589,000	11,089,000	8,213,000		12,267,000
long-term operating lease liabilities	4,629,000	3,565,000	5,815,000	6,267,000	6,415,000	5,191,000	5,755,000	5,832,000	10,991,000	11,183,000	10,336,000	34,893,000	27,088,000	16,758,000	15,494,000	11,467,000	4,771,000	6,081,000	5,643,000	3,920,000	9,181,000	9,231,000	9,970,000	9,932,000	10,489,000
other long-term liabilities	14,369,000	14,248,000	30,163,000	29,874,000	29,351,000	27,780,000	27,758,000	43,670,000	21,664,000	21,861,000	21,966,000	21,949,000	21,924,000	29,188,000	30,977,000	27,129,000	28,006,000	28,722,000	30,866,000	25,320,000	26,471,000	22,340,000	22,480,000	7,979,000	7,692,000	11,681,000	951,000	986,000	1,563,000	1,135,000	723,000	695,000	915,000	915,000	687,000	408,000	398,000	446,000	297,000	643,000	734,000	780,000	770,000	737,000	728,000	699,000	695,000	690,000	673,000	966,000	1,086,000	403,000	388,000	388,000	388,000	545,000	694,000	842,000	1,689,000	15,995,000	11,213,000	15,155,000	7,968,000	12,824,000	7,987,000	9,015,000	9,041,000	6,779,000	6,661,000	6,635,000	3,432,000	2,940,000	2,788,000	2,631,000	2,475,000	2,406,000	3,002,000	3,037,000	3,105,000	3,047,000	3,101,000	3,099,000	3,122,000	2,925,000	3,516,000	3,627,000	3,638,000	3,664,000
total liabilities	120,075,000	109,901,000	111,335,000	113,688,000	91,207,000	107,348,000	86,303,000	101,330,000	93,213,000	164,759,000	165,183,000	234,307,000	273,923,000	311,992,000	476,431,000	461,590,000	469,766,000	549,281,000	652,760,000	549,625,000	547,933,000	524,021,000	727,683,000	696,895,000	760,383,000	834,014,000	699,889,000	1,406,222,000	1,238,471,000	257,490,000	252,374,000	237,574,000	230,615,000	230,945,000	230,732,000	230,472,000	224,883,000	221,361,000	229,538,000	229,519,000	235,709,000	230,828,000	233,621,000	229,500,000	36,761,000	40,470,000	55,100,000	56,862,000	60,303,000	67,767,000	77,775,000	76,271,000	86,142,000	92,555,000	105,360,000	111,755,000	113,764,000	120,800,000	72,064,000	113,664,000	116,597,000	123,131,000	129,719,000	118,239,000	133,091,000	141,940,000	169,468,000	132,892,000	128,657,000	129,386,000	131,818,000	172,889,000	181,899,000	455,063,000	286,356,000	470,712,000	512,089,000	500,702,000	412,693,000	402,116,000	391,768,000	394,864,000	395,438,000	237,318,000	233,818,000	210,201,000	199,875,000	203,153,000	196,594,000	37,361,000
commitments and contingencies
stockholders' equity:
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2025 and december 31, 2024
common stock	20,000	20,000	20,000	19,000	19,000	18,000	18,000	18,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	17,000	16,000	16,000	16,000	16,000	17,000	17,000	19,000	20,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	28,000	21,000	21,000	20,000	20,000	20,000	20,000	20,000	20,000	21,000	21,000	21,000	22,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	21,000	124,000	123,000	123,000	119,000	119,000	119,000	119,000	101,000	101,000	101,000	101,000	100,000	101,000	100,000	100,000	78,000	78,000	78,000	73,000	73,000	73,000	73,000	73,000
additional paid-in capital	358,635,000	340,544,000	337,377,000	309,341,000	238,870,000	218,258,000	198,696,000	183,994,000	170,741,000	154,424,000	147,590,000	348,994,000	335,471,000	325,368,000	372,969,000	358,418,000	346,578,000	336,621,000	318,358,000	313,057,000	304,404,000	295,940,000	367,326,000	444,587,000	619,255,000	643,317,000	791,114,000	883,477,000	874,183,000	808,765,000	798,205,000	793,724,000	784,376,000	777,102,000	769,653,000	762,576,000	789,315,000	783,890,000	701,478,000	697,061,000	692,765,000	684,355,000	680,660,000	707,180,000	726,758,000	723,279,000	718,017,000	758,080,000	755,305,000	752,952,000	751,503,000	747,316,000	743,365,000	741,889,000	732,676,000	731,899,000	730,966,000	729,723,000	729,271,000	729,048,000	728,389,000	727,465,000	726,816,000	716,785,000	716,049,000	712,021,000	711,195,000	653,883,000	652,956,000	652,055,000	651,038,000	650,196,000	649,289,000	647,232,000	891,446,000	753,947,000	751,547,000	748,742,000	720,988,000	720,943,000	720,924,000	720,752,000	719,952,000	732,096,000	730,178,000	725,244,000	678,577,000	677,561,000	693,213,000	693,153,000
accumulated other comprehensive income	8,494,000																										-1,024,000	-64,000	-151,000	-286,000	2,486,000	3,335,000	3,059,000	3,105,000	2,743,000	3,652,000	3,745,000	3,568,000	4,903,000	5,558,000	11,265,000	9,334,000	4,953,000	3,543,000	5,041,000	10,943,000	2,914,000	2,201,000	1,395,000	1,166,000							0	5,000	31,000	76,000	885,000	1,021,000	513,000	317,000	94,000	11,000	81,000	103,000	-28,000	-43,000	9,000				-481,000	-138,000	30,000	1,021,000	490,000	-182,000	-420,000	-738,000	229,000						-43,000	-60,000
retained earnings	461,380,000	456,533,000	498,984,000	530,072,000	537,244,000	589,155,000	503,016,000	484,828,000	495,101,000	492,811,000	450,862,000	468,347,000	467,943,000	468,838,000	449,090,000	454,506,000	440,783,000	410,058,000	391,952,000	386,192,000	392,893,000	370,807,000	400,105,000	407,470,000	422,721,000	437,140,000
total stockholders' equity	828,529,000	795,534,000		841,178,000	775,198,000	806,521,000		667,896,000	664,892,000	646,317,000		816,298,000	802,365,000	793,192,000		812,066,000	786,517,000	745,840,000		697,824,000	695,003,000	661,896,000		850,581,000	1,041,453,000	1,079,974,000		699,520,000	619,813,000	481,100,000		403,166,000	385,116,000	371,830,000												65,001,000		44,815,000	39,268,000	30,596,000		21,235,000
total liabilities and stockholders' equity	948,604,000	905,435,000		954,866,000	866,405,000	913,869,000		769,226,000	758,105,000	811,076,000		1,050,605,000	1,076,288,000	1,105,184,000		1,273,656,000	1,256,283,000	1,295,121,000		1,247,449,000	1,242,936,000	1,185,917,000		1,547,476,000	1,801,836,000	1,913,988,000		2,105,742,000	1,858,284,000	754,668,000		662,337,000	640,024,000	629,723,000		600,865,000	616,799,000	613,438,000		521,700,000	304,762,000	263,223,000		272,283,000	99,847,000	105,471,000		101,677,000	99,571,000	98,363,000		97,506,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2025 and december 31, 2024
accumulated other comprehensive loss		-1,563,000	-5,942,000	1,746,000	-935,000	-910,000	-817,000	-944,000	-967,000	-935,000	-984,000	-1,060,000	-1,066,000	-1,031,000	-917,000	-875,000	-861,000	-856,000	-801,000	-1,441,000	-2,310,000	-4,867,000	-216,000	-1,493,000	-542,000	-503,000																																														-110,000	-155,000	-140,000										-127,000	-53,000	-88,000	-46,000	-61,000
prepaid expenses			1,934,000		1,911,000	1,237,000	1,182,000
operating lease right-of-use assets			6,907,000	7,157,000	7,403,000	6,028,000		6,235,000	11,392,000	11,666,000		32,108,000	24,711,000	15,783,000		12,951,000	6,500,000	7,611,000		4,269,000	9,689,000	9,630,000	10,353,000	10,280,000	10,964,000
finance lease right-of-use assets			2,766,000	2,940,000	3,085,000	3,219,000
equity method investment in primrose bio				1,245,000	2,437,000	10,469,000	12,595,000	13,985,000
liabilities and stockholders’ equity
income tax payable			1,199,000																					16,571,000	47,455,000	113,997,000																																		29,399,000	29,003,000	28,378,000	28,108,000
stockholders’ equity:
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2024 and 2023
total stockholders’ equity			830,439,000				700,913,000				597,485,000				821,159,000				709,525,000				767,232,000				560,914,000				399,788,000				341,290,000												49,613,000				26,485,000		18,452,000	19,243,000	8,646,000	2,367,000	5,327,000	5,009,000	-4,849,000	-9,440,000	2,656,000	2,145,000	3,744,000				-10,365,000	1,954,000	19,021,000	24,534,000	29,115,000	26,290,000	34,232,000	57,402,000	27,352,000									47,999,000	60,371,000	62,596,000	27,057,000	38,023,000	74,015,000	80,665,000
total liabilities and stockholders’ equity			941,774,000				787,216,000				762,668,000				1,297,590,000				1,362,285,000				1,494,915,000				1,260,803,000				671,021,000				601,585,000				533,929,000				258,029,000				104,713,000				104,260,000		104,594,000	111,798,000	122,350,000	122,466,000												147,191,000	160,023,000	166,265,000
current derivative assets				11,133,000	20,141,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at september 30, 2024 and december 31, 2023
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2024 and december 31, 2023
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2024 and december 31, 2023
commercial license and other economic rights							67,291,000				10,182,000				10,110,000	10,748,000	10,638,000	10,451,000	10,979,000	10,834,000	10,606,000	10,381,000	20,090,000	35,413,000	40,008,000	31,023,000
operating lease assets							6,062,000				10,914,000				16,542,000				6,892,000
finance lease assets							3,393,000				4,095,000				16,207,000				15,842,000
2023 convertible senior notes										76,790,000	76,695,000	76,600,000	114,974,000	176,540,000	320,717,000	316,889,000	315,318,000	352,313,000	442,293,000	454,973,000	449,672,000	444,432,000	638,959,000	631,533,000	624,209,000	616,987,000	609,864,000	602,839,000	595,912,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2023 and 2022
commercial license rights								6,602,000	10,783,000	10,431,000		10,193,000	10,267,000	10,121,000													31,460,000	20,934,000	20,437,000	19,969,000	19,526,000	23,721,000	22,962,000	25,630,000	25,821,000	25,985,000	26,141,000	8,546,000	8,554,000	8,598,000	8,598,000	4,568,000	4,568,000	4,568,000	4,567,000	4,571,000	4,571,000	4,571,000	4,571,000
financing lease right-of-use assets								3,566,000	3,762,000	3,943,000		14,444,000	15,032,000	15,620,000		16,795,000	17,383,000	17,950,000
equity securities in primrose bio								33,097,000
other current liabilities								916,000	448,000																											1,505,000	121,000	21,000	8,000	34,000	300,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at september 30, 2023 and december 31, 2022
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2023 and december 31, 2022
current financing lease liabilities										43,000		48,000	50,000	52,000		45,000	45,000	5,437,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2023 and december 31, 2022
current assets of discontinued operations
non-current assets of discontinued operations
current liabilities of discontinued operations
non-current liabilities of discontinued operations
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2022 and 2021
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at september 30, 2022 and december 31, 2021
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2022 and december 31, 2021
income taxes liability														5,800,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2022 and december 31, 2021
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2021 and 2020
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at september 30, 2021 and december 31, 2020
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2021 and december 31, 2020
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2021 and december 31, 2020
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2020 and 2019
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at september 30, 2020 and december 31, 2019
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at june 30, 2020 and december 31, 2019
investment in viking																						32,879,000	58,335,000	49,856,000	60,376,000	72,741,000	46,191,000	105,183,000	59,796,000	27,535,000	6,438,000	5,137,000	6,014,000	7,262,000	8,345,000				29,728,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at march 31, 2020 and december 31, 2019
derivative asset																									14,313,000	18,718,000	22,576,000	509,257,000	399,409,000
derivative liability																									14,313,000	18,718,000	23,430,000	563,158,000	401,291,000
2019 convertible senior notes																									27,087,000	26,756,000	26,433,000	213,144,000	210,370,000	227,547,000	224,529,000	221,557,000	218,630,000	215,748,000	212,910,000	210,115,000	207,363,000
preferred stock, 0.001 par value; 5,000 shares authorized; zero issued and outstanding at december 31, 2019 and 2018
preferred stock, 0.001 par value; 5,000 shares authorized; none issued and outstanding at september 30, 2019 and december 31, 2018
preferred stock, 0.001 par value; 5,000 shares authorized; none issued and outstanding at june 30, 2019 and december 31, 2018
preferred stock, 0.001 par value; 5,000 shares authorized; none issued and outstanding at march 31, 2019 and december 31, 2018
note receivable from viking																														3,877,000	3,877,000	3,007,000	3,207,000		3,207,000				4,782,000
equity component of currently redeemable convertible notes																														16,078,000	18,859,000	21,597,000	24,293,000	26,948,000	29,563,000	32,138,000
accumulated deficit																											-229,197,000	-183,914,000	-254,240,000	-327,400,000	-400,924,000	-393,914,000	-402,340,000	-408,398,000	-431,127,000	-428,001,000	-401,165,000	-395,402,000	-402,010,000	-410,458,000	-634,997,000	-658,561,000	-659,315,000	-666,371,000	-667,650,000	-669,242,000	-671,339,000	-673,208,000	-675,173,000	-681,263,000	-682,759,000	-683,822,000	-682,654,000	-680,387,000	-681,771,000	-687,273,000	-683,380,000	-682,460,000	-691,947,000	-696,451,000	-684,608,000	-684,330,000	-681,574,000	-684,584,000	-686,387,000	-684,715,000	-679,626,000	-609,999,000	-591,874,000	-585,445,000	-581,512,000	-587,450,000	-588,698,000	-588,879,000	-862,802,000	-1,004,166,000	-989,246,000	-973,288,000	-831,059,000	-828,337,000	-822,056,000	-813,132,000	-794,660,000	-683,133,000	-668,917,000	-661,722,000	-650,633,000	-638,636,000	-618,316,000	-611,588,000
restricted cash																												43,646,000															1,261,000																																38,814,000
current deferred revenue																													1,700,000													67,000		114,000
current lease exit obligations																																					239,000	577,000	934,000	1,300,000	1,638,000	1,999,000		2,526,000
note receivable from viking therapeutics																																				3,207,000	3,207,000	4,767,000		5,547,000
investment in viking therapeutics																																				17,339,000	18,733,000	28,118,000		31,826,000	33,996,000
total stockholders' equity attributable to ligand pharmaceuticals																																				338,255,000	391,916,000	392,077,000		292,181,000	69,053,000	35,148,000
long-term debt																																						204,653,000		202,951,000	200,567,000	198,219,000		193,631,000																																139,371,000	139,463,000	140,553,000	166,745,000	166,834,000	166,919,000	167,002,000	167,089,000	167,256,000	167,328,000	155,250,000	155,250,000	155,250,000	155,250,000
capitalized ipo expenses, vie																																										2,408,000	2,268,000
current debt issuance costs																																							860,000	847,000	834,000	822,000	809,000	793,000
long-term debt issuance costs																																							2,527,000	2,747,000	2,964,000	3,177,000	3,388,000	3,598,000
long-term notes payable																																							205,372,000
long-term lease exit obligations																																									228,000	577,000		1,133,000
long-term deferred income taxes
total stockholders’ equity attributable to parent																																							304,391,000				26,318,000
noncontrolling interests																																										-2,753,000	-1,910,000	-1,589,000	-1,084,000
total stockholder's equity																																							304,391,000				24,408,000
capitalized expenses
restricted investments																																								600,000	600,000																							1,341,000	1,341,000	1,341,000	1,341,000	1,411,000	1,411,000	1,411,000	1,411,000	1,411,000	1,561,000	1,826,000	1,826,000	1,826,000	1,826,000	1,826,000	1,826,000	1,826,000	1,826,000	1,656,000	2,378,000	1,656,000	1,656,000	6,203,000	6,204,000	10,741,000	10,646,000	1,848,000
note receivable																																									5,547,000
current co-promote termination payments receivable																																										88,000		523,000
restricted cash and investments																																										600,000		1,261,000	1,261,000	1,341,000	1,341,000	4,968,000	4,162,000	3,933,000	2,767,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,341,000	1,462,000
current deferred income taxes																																										258,000		1,574,000
current note payable, vie																																										348,000
current co-promote termination liability																																										88,000		523,000
current portion of co-promote termination payments receivable																																											322,000		391,000	688,000	4,329,000	4,507,000	4,472,000	4,257,000	4,327,000	4,431,000	4,934,000	5,898,000	6,197,000	8,030,000	8,029,000	8,030,000	8,034,000	9,780,000	9,777,000	9,716,000	9,782,000	11,925,000	11,518,000	11,197,000	10,958,000	10,824,000	8,682,000	8,651,000	10,467,000	14,740,000	13,962,000	11,881,000
long-term portion of co-promote termination payments receivable																																													413,000	448,000	7,417,000	8,387,000	8,579,000	7,916,000	8,207,000	8,644,000	9,822,000	14,226,000	15,255,000	20,616,000	21,346,000	22,060,000	22,851,000	28,618,000	29,386,000	29,057,000	30,993,000	45,374,000	46,146,000	46,806,000	47,524,000	47,911,000	50,298,000	50,726,000	48,989,000	80,935,000	81,010,000	81,015,000
current portion of contingent liabilities																																											6,796,000		2,877,000	1,094,000	1,712,000	1,879,000	780,000	356,000	356,000	323,000
current portion of deferred income taxes																																											257,000		1,574,000	1,574,000	1,574,000	1,581,000	1,581,000	8,000	1,581,000
current portion of notes payable (334 and 0 related to a vie, respectively																																											334,000
current portion of co-promote termination liability																																											322,000		391,000	688,000	4,329,000	4,507,000	4,472,000	4,257,000	4,327,000	4,431,000	4,934,000	5,898,000	6,197,000	8,030,000	8,029,000	8,030,000	8,034,000	9,780,000	9,777,000	9,716,000	9,782,000	11,925,000	11,518,000	11,197,000	10,958,000	10,824,000	8,682,000	8,651,000	10,467,000	14,740,000	13,962,000	13,083,000	12,179,000	47,722,000	45,046,000	42,533,000
current portion of lease exit obligations																																											2,356,000		2,689,000	2,754,000	2,811,000	2,860,000	2,910,000	3,015,000	3,039,000	2,987,000	3,054,000	3,160,000
current portion of deferred revenue																																											150,000		92,000		116,000	336,000	452,000	556,000	486,000	458,000	412,000	727,000	1,240,000		38,000	27,000			2,663,000	4,323,000	4,989,000	10,924,000	10,259,000	10,192,000	10,301,000								57,981,000	80,395,000	143,102,000	151,021,000	157,519,000	158,224,000	153,372,000	152,938,000	152,528,000	2,381,000	2,346,000	3,502,000	4,126,000		4,683,000
long-term portion of notes payable																																											195,908,000
long-term portion of co-promote termination liability																																													413,000	448,000	7,417,000	8,387,000	8,579,000	7,916,000	8,207,000	8,644,000	9,822,000	14,226,000	15,255,000	20,616,000	21,346,000	22,060,000	22,851,000	28,618,000	29,386,000	29,057,000	30,993,000	45,374,000	46,146,000	46,806,000	47,524,000	47,911,000	50,298,000	50,726,000	48,989,000	80,935,000	81,010,000	81,015,000	81,149,000	95,258,000	94,261,000	93,708,000
long-term portion of deferred revenue																																											2,085,000		2,085,000	2,085,000	2,085,000	2,085,000	2,085,000	2,125,000	2,369,000	2,538,000	2,722,000	3,370,000	3,466,000	1,291,000	1,291,000	2,546,000	2,546,000	2,546,000	2,546,000	2,546,000	3,495,000	4,866,000	8,421,000	10,380,000	16,819,000				2,546,000	2,546,000	2,546,000	2,546,000	2,546,000	2,546,000	4,100,000	4,124,000	4,202,000	4,279,000	4,357,000	4,434,000	4,512,000	2,120,000	2,198,000	2,352,000	2,430,000	2,709,000	3,014,000
long-term portion of lease exit obligations																																											934,000		1,587,000	2,339,000	3,071,000	3,725,000	4,305,000	5,074,000	5,963,000	6,534,000	7,355,000	7,716,000	8,367,000	9,171,000	9,861,000	10,548,000	11,118,000
long-term portion of deferred income taxes																																											2,792,000				1,098,000				725,000
long-term portion of contingent liabilities																																											8,353,000		12,223,000	12,743,000	11,795,000	8,552,000	9,219,000	12,384,000	10,543,000	7,735,000
capitalized expenses, vie																																												2,131,000
long-term co-promote termination payments receivable
current note payable																																												337,000
long-term co-promote termination liability
total stockholders' equity attributable to parent																																												44,372,000	64,170,000
capitalized ipo expenses, viking therapeutics, inc.																																													1,094,000
current portion of note payable																																													2,698,000	5,769,000	9,109,000	12,375,000	13,600,000	13,212,000	14,835,000	10,272,000	5,806,000	1,436,000
long-term portion of note payable																																																	1,970,000	5,494,000	13,443,000	17,876,000	22,211,000	26,435,000	20,286,000	20,200,000	20,114,000	20,029,000
commitments and contingencies-see note
treasury stock																																																-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,280,000	-42,225,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-42,134,000	-40,521,000	-36,446,000	-26,305,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000	-911,000
bank line of credit																																																					1,500,000	1,500,000	10,000,000	10,000,000	10,000,000	5,000,000
common stock subject to conditional redemption; 0 and 112,371 shares issued and outstanding at december 31, 2012 and 2011, respectively
common stock subject to conditional redemption; 0 and 112,371 shares issued and outstanding at september 30, 2012 and december 31, 2011, respectively
current portion of liability for contingent value rights																																																					3,739,000	2,449,000	6,879,000	6,446,000	5,955,000
long-term portion of liability for contingent value rights																																																					10,413,000	10,550,000	11,433,000
common stock subject to conditional redemption; 0 and 112,371 shares issued and outstanding at june 30, 2012 and december 31, 2011, respectively
stockholders’ equity
common stock subject to conditional redemption; 0 and 112,371 shares issued and outstanding at march 31, 2012 and december 31, 2011, respectively
income tax receivable																																																									0		4,575,000
accrued litigation settlement costs																																																									0		1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
current portion of deferred gain																																																								426,000	851,000	1,277,000	1,702,000	1,702,000	1,702,000	1,702,000	1,702,000	1,702,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000	1,964,000
current portion of lease termination payments																																																									0	5,300,000	5,296,000	5,292,000	9,786,000	4,493,000	4,487,000
common stock subject to conditional redemption; 112,371 shares issued and outstanding at december 31, 2011 and 2010, respectively																																																							8,344,000
goodwill and other identifiable intangible assets																																																								72,237,000	75,157,000	76,757,000	12,951,000	15,833,000	15,833,000	14,458,000	2,515,000	482,000	1,659,000	2,185,000	5,375,000
liability for contingent value rights																																																								14,294,000	15,006,000	17,341,000
common stock subject to conditional redemption; 112,371 shares issued and outstanding at september 30, 2011 and december 31, 2010, respectively																																																								8,344,000
common stock subject to conditional redemption; 112,371 shares issued and outstanding at june 30, 2011 and december 31, 2010, respectively																																																									8,344,000
convertible preferred stock, 0.001 par value; 833,333 shares authorized; none issued																																																									0
common stock subject to conditional redemption; 112,371 shares issued and outstanding at march 31, 2011 and december 31, 2010, respectively																																																										8,344,000
payable to neurogen stockholders																																																															3,770,000
long-term portion of deferred gain																																																												426,000	851,000	1,277,000	1,702,000	2,128,000	22,310,000	22,801,000	23,292,000	23,783,000	24,274,000	24,765,000	25,256,000	25,747,000	26,238,000	26,729,000	27,220,000
long-term portion of lease termination payments																																																														5,284,000	5,281,000
common stock subject to conditional redemption; 112,371 shares issued and outstanding at december 31, 2010 and 2009, respectively																																																											8,344,000
allowances for loss on returns, rebates and chargebacks related to discontinued operations																																																												1,000	14,000	19,000	31,000	354,000	1,275,000	5,590,000	9,590,000
current portion of equipment financing obligations																																																													39,000	81,000	91,000	172,000	241,000	349,000	1,829,000	716,000	978,000	1,238,000	1,528,000	1,810,000	1,989,000	2,151,000	2,168,000	2,150,000	2,146,000	2,298,000	2,401,000	2,488,000	2,638,000	2,651,000	2,604,000	2,453,000	2,439,000	2,299,000	1,890,000	2,105,000	2,087,000	2,342,000
common stock subject to conditional redemption; 112,371 shares issued and outstanding at september 30, 2010 and december 31, 2009																																																												8,344,000
stockholders’ equity :
common stock subject to conditional redemption; 674,230 shares issued and outstanding at june 30, 2010 and december 31, 2009																																																													8,344,000
convertible preferred stock, 0.001 par value; 5,000,000 shares authorized; none issued
common stock subject to conditional redemption; 674,230 shares issued and outstanding at march 31, 2010 and december 31, 2009																																																														8,344,000
restricted indemnity account																																																																		10,264,000	10,232,000	10,217,000	10,178,000	10,138,000	10,070,000	9,969,000	9,939,000	10,000,000
long-term portion of equipment financing obligations																																																																	25,000	54,000	2,178,000	172,000	266,000	403,000	627,000	889,000	1,259,000	1,641,000	2,156,000	2,699,000	2,851,000	3,251,000	3,430,000	3,361,000	3,910,000	4,113,000	4,003,000	3,547,000	3,518,000	2,682,000	3,403,000	3,707,000	4,095,000
common stock subject to conditional redemption; 674, 230 and 997,568 shares issued and outstanding at december 31, 2009 and 2008, respectively																																																															8,344,000
liabilities and stockholders’ deficit
current portion of accrued litigation settlement costs																																																																1,180,000	1,180,000	180,000	8,680,000
common stock subject to conditional redemption; 674,230 and 997,568 shares issued and outstanding at september 30, 2009 and december 31, 2008, respectively																																																																8,344,000
stockholders’ deficit:
total stockholders’ deficit																																																																-9,497,000	-12,259,000	-14,698,000										-251,190,000	-238,502,000	-224,358,000	-110,419,000	-108,414,000	-102,390,000	-93,956,000	-75,317,000
revenues:
royalties																																																																1,651,000	2,006,000	2,730,000
collaborative research and development and other revenues																																																																6,250,000	5,588,000	6,740,000											1,120,000	2,972,000	10,527,000	2,172,000	4,064,000	1,940,000	11,835,000
total revenues																																																																7,901,000	7,594,000	9,470,000										36,707,000	48,447,000	50,956,000	176,608,000	44,756,000	45,799,000	36,985,000	163,512,000
operating costs and expenses:
research and development																																																																9,921,000	9,470,000	10,462,000										10,468,000	13,895,000	12,218,000	56,075,000	12,911,000	14,524,000	14,735,000	65,204,000
general and administrative																																																																2,415,000	2,831,000	6,817,000
lease termination costs																																																																15,235,000
write-off of acquired in-process research and development.																																																																	441,000
total operating costs and expenses																																																																27,571,000	12,742,000	17,279,000										51,772,000	59,437,000	188,057,000	203,079,000	48,271,000	52,306,000	52,755,000	200,883,000
accretion of deferred gain on sale leaseback																																																																-20,444,000	-491,000	491,000
income from operations																																																																774,000	-4,657,000	-7,318,000										-15,065,000	-10,990,000	-137,101,000	-26,471,000	-3,515,000	-6,507,000	-15,770,000	-37,371,000
other income:
interest income																																																																176,000	120,000	139,000										577,000	587,000	573,000	1,890,000	483,000	398,000	444,000	1,096,000
interest expense																																																																-21,000	-42,000	-194,000										-2,547,000	-6,156,000	-6,067,000	-12,458,000	-3,172,000	-3,030,000	-3,127,000	-12,338,000
other																																																																126,000	103,000	-109,000										66,000	619,000	383,000	699,000	-60,000	232,000	1,000	3,705,000
total other income																																																																281,000	181,000	-164,000										-1,904,000	-4,950,000	-5,111,000	-9,869,000	-2,749,000	-2,400,000	-2,682,000	-7,537,000
income before income taxes																																																																1,055,000	-4,476,000	-7,482,000										-16,969,000	-15,940,000	-142,212,000		-6,264,000	-8,907,000	-18,452,000
income tax expense																																																																													-18,000	-17,000	-59,000	-17,000	-17,000	-20,000	-233,000
income from continuing operations																																																																1,055,000	-4,476,000	-7,482,000										-16,141,000
discontinued operations:
gain on sale of avinza product line before income tax benefit																																																																608,000
gain on sale of oncology product line before income tax benefit																																																																140,000
income tax benefit on discontinued operations
discontinued operations																																																																748,000	2,808,000	2,366,000
net income:																																																																1,803,000	-1,668,000
basic and diluted per share amounts:
net income																																																																20	-10	-5,116,000										-14,918,000	-15,958,000	-142,229,000	-36,399,000	-6,281,000	-8,924,000	-18,472,000	-45,141,000
weighted-average number of common shares - basic																																																																113,006,842,000
weighted-average number of common shares - diluted																																																																113,139,102,000
common stock subject to conditional redemption; 665,230 and 997,568 shares issued and outstanding at june 30, 2009 and december 31, 2008, respectively																																																																	8,344,000
income tax benefit																																																																												828,000
gain on sale of avinza product line before income taxes																																																																	2,592,000	2,131,000
gain on sale of oncology product line before income taxes																																																																	216,000	235,000
income tax benefit (expense) on discontinued operations
weighted-average number of common shares																																																																	113,147,714,000	113,118,073,000										78,670,137,000	78,539,820,000	77,496,969,000	74,019,501,000	74,041,204,000	74,036,753,000	73,916,470,000	73,692,987,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at march 31, 2009 and december 31, 2008, respectively																																																																		12,345,000
income tax expense on discontinued operations
common stock subject to conditional redemption; 997,568 shares issued and outstanding at december 31, 2008 and 2007, respectively																																																																			12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at september 30, 2008 and december 31, 2007																																																																				12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at june 30, 2008 and december 31, 2007																																																																					12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at march 31, 2008 and december 31, 2007																																																																						12,345,000
inventories																																																																																			11,772,000	11,752,000	9,770,000	6,005,000	4,806,000	5,395,000	4,841,000	3,155,000
acquired technology and product rights																																																																												84,990,000				150,271,000	153,773,000	144,275,000	127,443,000	132,520,000					148,546,000
note payable
common stock subject to conditional redemption; 997,568 shares issued and outstanding at december 31, 2007 and 2006, respectively																																																																							12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at september 30, 2007 and december 31, 2006																																																																								12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at june 30, 2007 and december 31, 2006																																																																									12,345,000
dividend payable																																																																										252,742,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at march 31, 2007 and december 31, 2006																																																																										12,345,000
current portion of inventories																																																																											3,856,000	5,039,000	8,467,000	8,232,000	9,333,000	6,868,000	6,328,000	6,896,000
long-term portion of inventories																																																																													5,211,000	5,486,000	5,869,000	8,007,000	8,727,000	6,020,000
acquired technology, product rights and royalty buy-down																																																																											83,083,000		139,766,000	143,268,000	146,770,000
current portion of debt																																																																											37,750,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at december 31, 2006 and 2005, respectively																																																																											12,345,000
current portion of assets held for sale																																																																												8,055,000
long-term portion of assets held for sale																																																																												57,807,000
current portion of long-term debt																																																																												363,000	356,000	350,000	344,000	337,000	331,000	325,000	320,000	303,000	303,000
current portion of liabilities related to assets held for sale																																																																												26,803,000
long-term portion of liabilities related to assets held for sale																																																																												2,017,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at september 30, 2006 and december 31, 2005																																																																												12,345,000
product sales																																																																												36,707,000	47,327,000	47,984,000	166,081,000	42,584,000	41,735,000	35,045,000	120,335,000
cost of products sold																																																																												5,800,000	10,266,000	9,740,000	39,847,000	9,807,000	10,667,000	11,065,000	39,804,000
selling, general and administrative																																																																												20,085,000	24,637,000	22,201,000	74,656,000	17,787,000	20,149,000	19,215,000	65,798,000
co-promotion																																																																												11,776,000	11,073,000	10,957,000	32,501,000	7,766,000	6,966,000	7,740,000	30,077,000
co-promote termination charges																																																																												3,643,000	-434,000	132,941,000
income from discontinued operations, net of income tax																																																																												1,223,000
income from discontinued operations																																																																												20
common stock subject to conditional redemption; 997,568 shares issued and outstanding at june 30, 2006 and december 31, 2005																																																																													12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at march 31, 2006 and december 31, 2005																																																																														12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at december 31, 2005 and 2004, respectively																																																																															12,345,000
sale of royalty rights																																																																																			31,342,000
income before income taxes and cumulative effect of a change in accounting principle																																																																															-36,340,000				-44,908,000
income before cumulative effect of a change in accounting principle																																																																															-36,399,000				-45,141,000
cumulative effect of changing method of accounting for variable interest entity
pro forma amounts assuming the changed method of accounting for variable interest entity is applied retroactively
basic and diluted net income per share
common stock subject to conditional redemption; 997,568 shares issued and outstanding at september 30, 2005 and december 31, 2004																																																																																12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at june 30, 2005 and december 31, 2004																																																																																	12,345,000
common stock subject to conditional redemption; 997,568 shares issued and outstanding at march 31, 2005 and december 31, 2004																																																																																		12,345,000
short-term investments; 9,204 restricted at december 31, 2003																																																																																			20,182,000
common stock subject to conditional redemption; 997,568 and 1,179,386 shares issued and outstanding at december 31, 2004 and 2003, respectively																																																																																			12,345,000
debt conversion expense
aquired technology and product rights																																																																																					135,189,000	140,526,000	143,194,000	145,862,000
accrued liabilites																																																																																					35,304,000	23,228,000	18,319,000	17,640,000		6,540,000
current portion of defferred revenue																																																																																								4,637,000		6,566,000
other long-term liabilites																																																																																									3,700,000
deferred warrant expense
aquired technology																																																																																										35,596,000
convertible note																																																																																										2,500,000
long term portion of deferred revenue																																																																																										3,319,000
long term portion of equipment financing obligations																																																																																										3,732,000
accrued acquisition obligation																																																																																										2,700,000
convertible subordinated debentures
zero coupon convertible senior notes

We provide you with 20 years of balance sheets for Ligand Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ligand Pharmaceuticals. Explore the full financial landscape of Ligand Pharmaceuticals stock with our expertly curated balance sheets.

The information provided in this report about Ligand Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.